grant
Mechanism and Inhibition of HIV Reverse Transcriptase
NIHUS FederalResearch GrantFY2025AIDSAIDS VirusAIDS therapyAcquired Immune DeficiencyAcquired Immune Deficiency SyndromeAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency SyndromeAcquired Immunodeficiency Syndrome VirusAnti-HIV resistanceAnti-HIV resistantCapsidCausalityCell BodyCell DeathCellsCombined Modality TherapyDevelopmentDimerizationDiseaseDisorderDoseDrug CombinationsDrug TargetingDrug resistanceDrug resistance in HIVDrugsEC 2.7.7.49EtiologyFamilyFormulationGenomeHIVHIV ProteaseHIV ProteinaseHIV drug resistanceHIV drug resistantHTLV-III ProteaseHuman Immunodeficiency VirusesInflammasomeLAV-HTLV-IIILymphadenopathy-Associated VirusMediatingMedicationMolecular TargetMultimodal TherapyMultimodal TreatmentNew AgentsNon-Polyadenylated RNAPathway interactionsPatient CompliancePersonsPharmaceutical PreparationsPrEPPropertyProtein DimerizationRNARNA Gene ProductsRNA TranscriptaseRNA-Dependent DNA PolymeraseRNA-Directed DNA PolymeraseRegimenResistance profileResistant profileReverse TranscriptaseRevertaseRibonucleic AcidSafetyStructureTherapeuticVariantVariationViralVirus ReplicationVirus-HIVWorld Health Organizationantiretroviral therapyantiretroviral treatmentcausationcell killingclinical relevanceclinically relevantcombatcombination therapycombined modality treatmentcombined treatmentdesigndesigningdevelopmentaldisease causationdrug resistantdrug resistant HIVdrug/agenteffective therapyeffective treatmentimprovedinhibitorlead optimizationmembermouse modelmulti-modal therapymulti-modal treatmentmurine modelnecrocytosisnew approachesnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel approachesnovel drug treatmentsnovel drugsnovel lead compoundnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel strategiesnovel strategynovel therapeuticsnovel therapynucleoside inhibitorpathwaypatient adherencepatient cooperationpharmacologicpre-clinicalpre-exposure prophylaxispreclinicalprematureprematurityprophylacticresistance strainresistance to Drugresistance to HIV drugresistance to anti-HIVresistant strainresistant to Drugresistant to HIV drugside effectsynergismviral multiplicationviral replicationvirus multiplication
Description preview
PROJECT SUMMARY / ABSTRACT
The HIV-1 (Human Immunodeficiency Virus) is a member of the retroviral family which contains a single-stranded
RNA genome and is the major etiological agent involved in the development of acquired immunodeficiency
syndrome or AIDS. The WHO now estimates that in 2022 over 40 million people worldwide are infected.…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click